AVDL vs. RNA, SRRK, MLTX, MTSR, VKTX, MOR, KYMR, ALVO, IMVT, and CRNX
Should you be buying Avadel Pharmaceuticals stock or one of its competitors? The main competitors of Avadel Pharmaceuticals include Avidity Biosciences (RNA), Scholar Rock (SRRK), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Viking Therapeutics (VKTX), MorphoSys (MOR), Kymera Therapeutics (KYMR), Alvotech (ALVO), Immunovant (IMVT), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry.
Avadel Pharmaceuticals vs. Its Competitors
Avidity Biosciences (NASDAQ:RNA) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.
Avidity Biosciences currently has a consensus price target of $65.59, suggesting a potential upside of 125.16%. Avadel Pharmaceuticals has a consensus price target of $18.17, suggesting a potential upside of 103.55%. Given Avidity Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Avidity Biosciences is more favorable than Avadel Pharmaceuticals.
Avadel Pharmaceuticals has higher revenue and earnings than Avidity Biosciences. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks.
Avadel Pharmaceuticals has a net margin of -13.58% compared to Avidity Biosciences' net margin of -4,136.00%. Avidity Biosciences' return on equity of -26.96% beat Avadel Pharmaceuticals' return on equity.
Avidity Biosciences has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500.
69.2% of Avadel Pharmaceuticals shares are held by institutional investors. 3.8% of Avidity Biosciences shares are held by insiders. Comparatively, 5.2% of Avadel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Avadel Pharmaceuticals had 6 more articles in the media than Avidity Biosciences. MarketBeat recorded 9 mentions for Avadel Pharmaceuticals and 3 mentions for Avidity Biosciences. Avidity Biosciences' average media sentiment score of 0.12 beat Avadel Pharmaceuticals' score of -0.03 indicating that Avidity Biosciences is being referred to more favorably in the media.
Summary
Avadel Pharmaceuticals beats Avidity Biosciences on 9 of the 17 factors compared between the two stocks.
Get Avadel Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVDL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding AVDL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avadel Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:AVDL) was last updated on 7/4/2025 by MarketBeat.com Staff
Free AVDL Stock Alerts